Clovis Oncology reported $-42347000 in EBITDA for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Agenus AGEN:US USD -39945000 3.34M
Agios Pharmaceuticals AGIO:US USD -89109000 6.24M
Arrowhead Research ARWR:US USD -81170000 10.86M
AstraZeneca AZN:LN USD 3.6B 404M
Astrazeneca AZN:US USD 3.6B 404M
Clovis Oncology CLVS:US USD -42347000 15.13M
Eli Lilly And LLY:US USD 2.31B 308.9M
Esperion Therapeutics ESPR:US USD -41518000 10.71M
GlaxoSmithKline GSK:LN GBP 3.36B 916M
Halozyme Therapeutics HALO:US USD 112.9M 66.29M
Insmed INSM:US USD -119864000 21.78M
Intrexon XON:US USD -5899000 15.79M
Mirati Therapeutics MRTX:US USD -185727000 9.22M
Neurocrine Biosciences NBIX:US USD 91.8M 33.2M
Novartis NOVN:VX USD 4.69B 34M
Pfizer PFE:US USD 10.52B 2.78B
Sangamo Biosciences SGMO:US USD -51845000 8.99M
Seattle Genetics SGEN:US USD -175213000 59.32M
Ultragenyx Pharmaceutical RARE:US USD -220372000 83.26M
Veracyte VCYT:US USD -3356000 2.42M
YTE INCY:US USD 134.94M 141.85M